OncoMatch/Clinical Trials/NCT04727307
Neoadjuvant Atezo, Adjuvant Atezo + Beva Combined With RF Ablation of Small HCC: a Multicenter Randomized Phase II Trial
Is NCT04727307 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Atezolizumab (neoadjuvant) and Bevacizumab (adjuvant) for hepatocellular carcinoma.
Treatment: Atezolizumab (neoadjuvant) · Bevacizumab (adjuvant) · Atezolizumab (adjuvant) — Following the results of study IMbrave150, the combination Atezolizumab + Bevacizumab is a promising treatment option for patients with HCC. In addition, the high intrahepatic distant recurrence rate and accumulating evidence for a metastatic mechanism encourages exploring adjuvant/neoadjuvant strategies targeting tumor growth and metastatic escape in the context of percutaneous thermal ablation for small HCC. Local ablation of HCC is therefore an "ideal" setting for testing atezolizumab + bevacizumab in combination with ablation, with the aim of reducing the risk of recurrence.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: liver transplantation
Prior liver transplantation
Cannot have received: chemo-embolization
Prior chemo-embolization
Cannot have received: radio-embolization
Prior radio-embolization
Cannot have received: surgery of HCC with micro- or macro-vascular invasion
Prior surgery of HCC with micro- or macro-vascular invasion demonstrated at pathology
Cannot have received: systemic treatment for HCC
Prior systemic treatment for HCC, in particular agents targeting T-cell costimulation or checkpoint pathways (including those targeting PD-1, PD-L1 or PD-L2, cluster of differentiation 137 (CD137), or cytotoxic T-lymphocyte antigen (CTLA-4))
Lab requirements
Blood counts
Hemoglobin > 8.5 g/dL; Absolute neutrophil count ≥ 1500/mm3; Platelet count ≥ 50,000/ mm3; Prothrombin time > 50%
Kidney function
Serum creatinine ≤ 1.5 x ULN; Glomerular Filtration Rate (GFR) ≥ 35 mL/min/1.73 m2
Liver function
Total bilirubin ≤ 2 mg/dL (ou ≤ 34 µmol/ L). Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 5 x upper limit of normal (ULN)
Adequate bone marrow, liver and renal function as assessed by the following laboratory tests: Hemoglobin > 8.5 g/dL; Absolute neutrophil count ≥ 1500/mm3; Platelet count ≥ 50,000/ mm3; Total bilirubin ≤ 2 mg/dL (ou ≤ 34 µmol/ L). Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 5 x upper limit of normal (ULN); Serum creatinine ≤ 1.5 x ULN; Lipase ≤ 2 x ULN; Prothrombin time > 50%; Glomerular Filtration Rate (GFR) ≥ 35 mL/min/1.73 m2
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify